Comparative Pharmacology
Head-to-head clinical analysis: ASENDIN versus AVENTYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASENDIN versus AVENTYL.
ASENDIN vs AVENTYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxapine, a dibenzoxazepine tricyclic antidepressant, primarily inhibits the reuptake of norepinephrine and serotonin. Its metabolite, 7-hydroxyamoxapine, exhibits dopamine D2 receptor antagonism, contributing to its antipsychotic effects.
Nortriptyline, the active ingredient, inhibits the reuptake of norepinephrine and serotonin in the central nervous system, potentiating their effects. It also has anticholinergic and antihistaminergic properties.
50 mg orally three times daily, increased gradually to 100-200 mg/day in divided doses. Max 300 mg/day.
Adults: 25 mg orally 3 to 4 times daily, maximum 150 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours. Clinical context: Steady-state is reached within 5-7 days; the half-life supports once-daily dosing in most patients.
Terminal elimination half-life: 19-24 hours; requires 4-6 days to reach steady state.
Renal (approximately 50% as unchanged drug and metabolites), biliary/fecal (30-40%), with the remainder as other metabolites; <10% excreted unchanged in urine.
Renal (30% as unchanged drug and metabolites); biliary/fecal (70% as metabolites)
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant